Heberprot-P
A recombinant human Epidermal Growth Factor therapy injected directly into diabetic foot ulcers to stimulate tissue healing and reduce the risk of amputation.
Heberprot-P
A recombinant human Epidermal Growth Factor therapy injected directly into diabetic foot ulcers to stimulate tissue healing and reduce the risk of amputation.
Heberprot-P at a glance
Heberprot-P is a unique Cuban biotechnology product developed by the Center for Genetic Engineering and Biotechnology (CIGB) in Havana. It contains a recombinant (lab-made) human Epidermal Growth Factor (hEGF) — a protein that helps skin and tissue cells grow and heal. It is given by injection directly into the edges of complex diabetic foot ulcers (open wounds on the feet that are hard to heal), offering a treatment option for wounds that have not responded to standard care.
How It Works
Epidermal Growth Factor (EGF) is a natural protein that stimulates cell growth, proliferation, and differentiation. In diabetic foot ulcers, the normal healing process is impaired due to poor blood flow, nerve damage, and high blood sugar. Heberprot-P delivers recombinant hEGF directly to the wound bed, where it stimulates cell proliferation and tissue regeneration — promoting wound closure in ulcers that have not healed with standard wound care alone.
Treatment Protocol
Heberprot-P is injected directly into the wound edges (intralesional injection), usually three times per week for up to 8 weeks. The treatment is combined with standard wound care: cleaning, removal of dead tissue (debridement), proper dressings, pressure relief (offloading), infection treatment, and blood sugar control. The injections are administered by trained specialists in Cuban clinics, with comprehensive diabetes management alongside.
Conditions Treated
Clinical Evidence
Heberprot-P is registered in more than 26 countries and has been used to treat thousands of patients. Clinical studies have shown significant healing rates in ulcers that did not respond to standard treatment. Individual results vary based on the wound characteristics, vascular status, glycemic control, and the patient's overall health.
Availability
Heberprot-P is registered in Cuba and more than 26 other countries. It is available to international patients through SMC Salud's international patient services. The treatment requires travel to Cuba, as the injections must be administered by trained specialists in a clinical setting.
Frequently Asked Questions
Related Information
Medically Reviewed
SMC Salud Medical Review Board
Board-certified physicians and specialists in oncology, neurology, dermatology, and endocrinology
Last reviewed: January 15, 2025
This content has been medically reviewed by qualified physicians and follows SMC Salud's editorial policy for health information. Medical content is for informational purposes and does not replace professional medical advice.
Ready to Learn More?
Take the next step. Our international patient coordinators are here to help you understand your options.
Treatment suitability depends on specialist evaluation. Individual treatment plans apply.